AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update (English only)
- Three clinical readouts delivered year to date; four more expected by year-end
- First patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study inpatients with prodromal Alzheimer’s disease and individuals with Down syndrome
- Crenezumab API ADAD study results to be presented in detail at AAIC on August 2 after top-line data showed numerical differences favoring crenezumab over placebo across the majority of endpoints, though not statistically significant
- Strong financial position of CHF 154.1 million ensures the Company is fully financed until Q1 2024 not considering any incoming milestone payments
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the quarter ended June 30, 2022, and provided a corporate update.